The development of folic acid–based radioconjugates has been proposed for imaging and targeted radionuclide therapy of folate receptor-α (FRα)–positive cancer. Although folic acid binds both the tumor ...

Journal of Nuclear Medicine April 2025, jnumed.124.268980; DOI: https://doi.org/10.2967/jnumed.124.268980 ...

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by ...

Journal of Nuclear Medicine July 2025, jnumed.125.270252; DOI: https://doi.org/10.2967/jnumed.125.270252 ...

Accurate delineation of the intraprostatic gross tumor volume (GTV) is a prerequisite for treatment approaches in patients with primary prostate cancer (PCa). Prostate-specific membrane antigen PET ...

Journal of Nuclear Medicine January 2026, jnumed.125.269933; DOI: https://doi.org/10.2967/jnumed.125.269933 ...

Journal of Nuclear Medicine October 2025, jnumed.124.269188; DOI: https://doi.org/10.2967/jnumed.124.269188 ...

Journal of Nuclear Medicine March 2026, jnumed.125.271601; DOI: https://doi.org/10.2967/jnumed.125.271601 ...

Fibroblast activation protein (FAP), a member of the serine protease family, is expressed in the microenvironment of more than 90% of epithelial tumors, including pancreas, colon, breast, and ENT (ear ...

Cancer remains one of the leading causes of death worldwide (1). Although morphologic imaging techniques to detect and monitor malignant diseases have advanced over the last few decades, limitations ...

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor frequently expressed in solid malignancies, such as glioblastoma and melanoma, with limited expression in healthy tissue, rendering it ...

Journal of Nuclear Medicine March 2026, jnumed.125.271976; DOI: https://doi.org/10.2967/jnumed.125.271976 ...